Valuation: Pharmadrug Inc.

Market Cap 671K 475K 418K 390K 358K 45.58M 682K 4.61M 1.8M 22.55M 1.79M 1.75M 77.95M P/E 2024
-1.31x
P/E 2025 -4.23x
Enterprise Value 2.17M 1.54M 1.35M 1.26M 1.16M 148M 2.21M 14.91M 5.83M 72.98M 5.78M 5.66M 252M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
77.22%
Yield 2024 *
-
Yield 2025 -
1 week-50.00%
1 month-50.00%
3 months-66.67%
6 months-66.67%
Current year-66.67%
1 week 0
Extreme 0.005
0
1 month 0
Extreme 0.005
0.01
Current year 0
Extreme 0.005
0.02
1 year 0
Extreme 0.005
0.02
3 years 0
Extreme 0.005
0.08
5 years 0
Extreme 0.005
0.46
10 years 0
Extreme 0.005
4.55
Manager TitleAgeSince
Director of Finance/CFO 50 20/10/2023
Director TitleAgeSince
Director/Board Member 82 20/12/2016
Chairman - 27/02/2024
Date Insider Type Main position Quantity % Market Cap.
14/10/25 Other

Chairman

1,380,000 1.2929%
03/05/24 Other

Director

0 0%
03/05/24 Option

Director

500,000 0.5718%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-50.00%-50.00%-85.71% 476K
+4.64%+6.98%+24.96%+119.35% 99.52B
+1.38%+2.99%+47.96%+151.55% 53.72B
+1.40%-1.02%+2.11%+271.79% 23.01B
-0.06%-2.78%-13.33%-19.68% 8.19B
+0.21%-7.75%-32.34%-35.45% 7.47B
+0.47%-2.10%-10.71%-29.59% 6.83B
+0.77%-1.08%+19.94%+27.50% 6.14B
+0.92%-1.62%+0.29%+22.92% 5.31B
-1.18%-2.90%-6.86%-8.24% 3.74B
Average +0.86%-1.42%-1.80%+41.44% 21.39B
Weighted average by Cap. +2.70%+0.69%+22.36%+121.09%

Financials

2024 2025
Net sales - -
Net income -793K -562K -494K -461K -423K -53.88M -807K -5.44M -2.13M -26.66M -2.11M -2.07M -92.15M -383K -272K -239K -223K -205K -26.04M -390K -2.63M -1.03M -12.88M -1.02M -998K -44.53M
Net Debt 1.27M 902K 793K 740K 680K 86.53M 1.3M 8.74M 3.42M 42.81M 3.39M 3.32M 148M 1.5M 1.06M 935K 872K 801K 102M 1.53M 10.3M 4.03M 50.43M 4M 3.91M 174M
Logo Pharmadrug Inc.
PharmaDrug Inc. is a Canada-based specialty pharmaceutical company. The Company is focused on the research, development and commercialization of controlled substances and natural medicines, such as psychedelics and previously approved drugs. The Company’s subsidiary, Sairiyo Therapeutics (Sairiyo), is a biotech company that specializes in researching and reformulating established natural medicines. Sairiyo is engaged in the development of its patented reformulation of cepharanthine, a drug that has shown substantial third-party validated potential for the treatment of infectious diseases and rare cancers. Sairiyo is also conducting research and development (R&D) in the psychedelics space for the treatment of non-neuropsychiatric conditions. It also owns 100% of SecureDose Synthetics Inc. a pharmaceutical research and development company focused on the development of synthetic formulations of existing drugs for potential commercialization and distribution.
Employees
-
Date Price Change Volume
  1. Stock Market
  2. Stocks
  3. PHRX Stock